Annual D&A
$6.22 M
+$2.48 M+66.14%
December 31, 2023
Summary
- As of February 7, 2025, GLUE annual depreciation & amortization is $6.22 million, with the most recent change of +$2.48 million (+66.14%) on December 31, 2023.
- During the last 3 years, GLUE annual D&A has risen by +$5.68 million (+1058.66%).
- GLUE annual D&A is now at all-time high.
Performance
GLUE Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
Quarterly D&A
$2.10 M
+$43.00 K+2.09%
September 30, 2024
Summary
- As of February 7, 2025, GLUE quarterly depreciation & amortization is $2.10 million, with the most recent change of +$43.00 thousand (+2.09%) on September 30, 2024.
- Over the past year, GLUE quarterly D&A has increased by +$206.00 thousand (+10.86%).
- GLUE quarterly D&A is now at all-time high.
Performance
GLUE Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM D&A
$7.91 M
+$269.00 K+3.52%
September 30, 2024
Summary
- As of February 7, 2025, GLUE TTM depreciation & amortization is $7.91 million, with the most recent change of +$269.00 thousand (+3.52%) on September 30, 2024.
- Over the past year, GLUE TTM D&A has increased by +$938.00 thousand (+13.46%).
- GLUE TTM D&A is now at all-time high.
Performance
GLUE TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
GLUE Depreciation And Amortization Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +66.1% | +10.9% | +13.5% |
| 3 y3 years | +1058.7% | +96.5% | +111.1% |
| 5 y5 years | +8541.7% | +96.5% | +111.1% |
GLUE Depreciation And Amortization Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +191.8% | at high | +179.3% | at high | +270.8% |
| 5 y | 5-year | at high | +8541.7% | at high | +2862.0% | at high | >+9999.0% |
| alltime | all time | at high | +8541.7% | at high | +2862.0% | at high | >+9999.0% |
Monte Rosa Therapeutics Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $2.10 M(+2.1%) | $7.91 M(+3.5%) |
| Jun 2024 | - | $2.06 M(+8.6%) | $7.64 M(+9.6%) |
| Mar 2024 | - | $1.90 M(+2.8%) | $6.97 M(+12.0%) |
| Dec 2023 | $6.22 M(+66.1%) | $1.85 M(+0.7%) | $6.22 M(+14.2%) |
| Sep 2023 | - | $1.83 M(+31.8%) | $5.45 M(+17.2%) |
| Jun 2023 | - | $1.39 M(+20.9%) | $4.64 M(+12.1%) |
| Mar 2023 | - | $1.15 M(+7.6%) | $4.14 M(+10.6%) |
| Dec 2022 | $3.75 M | $1.07 M(+3.6%) | $3.75 M(+7.5%) |
| Sep 2022 | - | $1.03 M(+16.2%) | $3.48 M(+14.9%) |
| Jun 2022 | - | $889.00 K(+18.1%) | $3.03 M(+16.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $753.00 K(-6.9%) | $2.61 M(+22.5%) |
| Dec 2021 | $2.13 M(+297.0%) | $809.00 K(+39.0%) | $2.13 M(+37.9%) |
| Sep 2021 | - | $582.00 K(+24.6%) | $1.55 M(+36.2%) |
| Jun 2021 | - | $467.00 K(+70.4%) | $1.14 M(+53.4%) |
| Mar 2021 | - | $274.00 K(+22.9%) | $740.00 K(+37.8%) |
| Dec 2020 | $537.00 K(+645.8%) | $223.00 K(+30.4%) | $537.00 K(+71.0%) |
| Sep 2020 | - | $171.00 K(+137.5%) | $314.00 K(+119.6%) |
| Jun 2020 | - | $72.00 K(+1.4%) | $143.00 K(+101.4%) |
| Mar 2020 | - | $71.00 K | $71.00 K |
| Dec 2019 | $72.00 K | - | - |
FAQ
- What is Monte Rosa Therapeutics annual depreciation & amortization?
- What is the all time high annual D&A for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual D&A year-on-year change?
- What is Monte Rosa Therapeutics quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly D&A year-on-year change?
- What is Monte Rosa Therapeutics TTM depreciation & amortization?
- What is the all time high TTM D&A for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics TTM D&A year-on-year change?
What is Monte Rosa Therapeutics annual depreciation & amortization?
The current annual D&A of GLUE is $6.22 M
What is the all time high annual D&A for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual depreciation & amortization is $6.22 M
What is Monte Rosa Therapeutics annual D&A year-on-year change?
Over the past year, GLUE annual depreciation & amortization has changed by +$2.48 M (+66.14%)
What is Monte Rosa Therapeutics quarterly depreciation & amortization?
The current quarterly D&A of GLUE is $2.10 M
What is the all time high quarterly D&A for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly depreciation & amortization is $2.10 M
What is Monte Rosa Therapeutics quarterly D&A year-on-year change?
Over the past year, GLUE quarterly depreciation & amortization has changed by +$206.00 K (+10.86%)
What is Monte Rosa Therapeutics TTM depreciation & amortization?
The current TTM D&A of GLUE is $7.91 M
What is the all time high TTM D&A for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high TTM depreciation & amortization is $7.91 M
What is Monte Rosa Therapeutics TTM D&A year-on-year change?
Over the past year, GLUE TTM depreciation & amortization has changed by +$938.00 K (+13.46%)